Does fostatinib affect blood sugar levels?

Fostamatinib is a tyrosine kinase inhibitor that exerts immunomodulatory effects mainly by inhibiting spleen tyrosine kinase (SYK) and has been approved for the treatment of chronic immune thrombocytopenia (ITP). Since its mechanism of action involves immune system regulation and inflammatory response, it may have a certain impact on metabolic processes, but has relatively little direct effect on blood sugar levels.

Current clinical study data do not show that fostatinib will significantly increase or decrease blood glucose levels, but individual patients may experience metabolic abnormalities. Fostatinib reduces the inflammatory response by inhibiting the SYK pathway and may indirectly improve insulin resistance related to chronic inflammation, but its specific impact has not been widely confirmed. Therefore, patients with diabetes still need to closely monitor blood glucose levels during treatment with fostatinib.

In addition, common adverse reactions of fostatinib include hypertension, diarrhea, and liver function abnormalities, which may indirectly affect glycemic control. For example, diarrhea may lead to inadequate nutrient intake, which affects blood sugar level fluctuations, while liver damage may alter insulin metabolism. Therefore, patients with metabolic diseases need to pay special attention to related complications during medication.

Overall, the direct effect of fostatinib on blood glucose levels is unclear, but given individual differences and potential metabolic effects, patients with diabetes or metabolic diseases should receive routine blood glucose monitoring during treatment. Doctors need to comprehensively assess the patient's overall health status when making treatment decisions and adjust the blood sugar management plan as needed to ensure the safety and effectiveness of treatment.

Reference materials:https://www.tavalisse.com/